Aptevo Therapeutics
2401 4th Avenue
Suite 1050
Seattle
Washington
98121
United States
Website: http://aptevotherapeutics.com/
83 articles with Aptevo Therapeutics
-
Aptevo Therapeutics Files Provisional Patent for Fifth Bispecific Antibody APVO711, Intended for the Treatment of Solid Tumors
1/9/2023
Aptevo Therapeutics Inc. today announced that the Company has filed a provisional patent with the U.S. Patent and Trademark Office (USPTO) pertaining to an anti-PD-L1 x anti-CD40 compound, APVO711, with the potential to fight a range of solid malignancies such as head and neck squamous cell carcinoma, melanoma, and carcinomas of the lung, gastrointestinal tract and colon.
-
100% Clinical Benefit Rate Achieved in Phase 1b Trial Evaluating APVO436 in Combination with Venetoclax and Azacitidine for Venetoclax Treatment Naïve Patients with Acute Myeloid Leukemia (AML)
12/12/2022
Aptevo Therapeutics Plans a Phase 2 Trial in 2H23 in Frontline and Relapsed/Refractory Patients who are Venetoclax Treatment Naive.
-
Alligator Bioscience and Aptevo Therapeutics Announce that FDA has Issued a "May Proceed" Notification for the ALG.APV-527 IND
9/19/2022
Alligator Bioscience AB today announced that the US Food and Drug Administration (FDA) has issued a notification for the ALG.APV-527 investigational new drug application (IND), allowing the companies to initiate clinical trials evaluating the compound for the treatment of 5T4-expressing tumor antigens in multiple solid tumor types.
-
Aptevo Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights
8/11/2022
Aptevo Therapeutics Inc. today reported financial results and business highlights for the quarter ended June 30, 2022.
-
Aptevo Therapeutics Announces New Preliminary Remission Data on Four Additional Patients Enrolled in On-going APVO436 Dose Expansion Phase 1b Trial for the Treatment of Acute Myeloid Leukemia
6/9/2022
Aptevo Therapeutics Inc. today announced new remission data on four additional patients.
-
Aptevo Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights
5/12/2022
Aptevo Therapeutics Inc. today reported financial results and business highlights for the quarter ended March 31, 2022.
-
APVO442 Prostate Cancer Data Presented at the American Association for Cancer Research Annual Meeting
4/12/2022
Aptevo Therapeutics Inc. today announced the presentation of preclinical data for APVO442 in a poster session at the American Association for Cancer Research (AACR) Annual Meeting in New Orleans, LA.
-
Aptevo Therapeutics Announces Monotherapy Patient Received a Transplant in APVO436 Expansion Trial for the Treatment of Acute Myeloid Leukemia
3/29/2022
Aptevo Therapeutics Inc. today announced that a patient with relapsed/refractory acute myeloid leukemia or AML in a monotherapy arm of its on-going Phase 1b trial evaluating adult patients with AML, has received an allogeneic stem cell transplant subsequent to receiving APVO436 and experiencing significant reduction in bone marrow blasts.
-
Aptevo Therapeutics Reports 2021 Financial Results and Provides Business Update
3/24/2022
Aptevo Therapeutics Inc. today reported its financial results for the year ended December 31, 2021 and provided 2021 business highlights.
-
Aptevo Therapeutics Earns $10 Million Non-Dilutive Milestone Payment on Sales of RUXIENCE, Provides Company Update
2/9/2022
Aptevo Therapeutics Inc. today announced that the Company has earned a $10 million non-dilutive milestone payment related to 2021 sales of RUXIENCE®.
-
Aptevo Therapeutics' Board Chairman, Fuad El-Hibri, Announces Retirement, Effective April 1, 2022
1/21/2022
Aptevo Therapeutics Inc. today announced that founding chairman of the board, Fuad El-Hibri, has announced his retirement effective April 1, 2022. The Company also announced that long-time board member and vice chairman John E. Niederhuber, M.D., will assume the chairmanship, effective April 1, 2022.
-
Alligator Bioscience & Aptevo Therapeutics Announce Co-Publication in Peer-Reviewed Journal Nature Communication
12/15/2021
Alligator Bioscience AB ("Alligator") and Aptevo Therapeutics ("Aptevo") (NASDAQ: APVO) today announced publication of an article in the December 15, 2021, issue of the peer-reviewed journal, Nature Communications on the mechanism of action of CD137 (4-1BB) targeting bispecific antibodies.
-
Alligator Bioscience & Aptevo Therapeutics Announce Co-Publication in Peer-Reviewed Journal, "Nature Communication"
12/15/2021
Alligator Bioscience AB today announced publication of an article in the December 15, 2021, issue of the peer-reviewed journal, Nature Communications, on the mechanism of action of 4-1BB targeting bispecific antibodies.
-
Clinical Catch-Up: November 22-26
11/29/2021
Thanksgiving week was marked by numerous clinical trial announcements. Here’s a look. -
Aptevo Therapeutics Reports First Complete Remission, Providing Clinical Update for Its Phase 1b Multi Center, Multi Cohort Expansion Trial in the Treatment of Acute Myeloid Leukemia
11/23/2021
Aptevo Therapeutics Inc. today announced a clinical update for the Company's Phase 1b Expansion trial evaluating APVO436 in the treatment of acute myeloid leukemia (AML).
-
Positive data from an ongoing Phase Ib study has impressed investors in Aptevo Therapeutics.
-
Aptevo Therapeutics Announces the Presentation of Two Abstracts at the Upcoming American Society of Hematology Annual Meeting
11/15/2021
Aptevo Therapeutics Inc. today announced that the Company will present two abstracts at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition
-
Aptevo Therapeutics Reports Third Quarter Financial Results With Business Highlights
11/12/2021
Aptevo Therapeutics Inc. today reported its financial results and business highlights for the quarter ended September 30, 2021.
-
Aptevo Therapeutics Announces Preclinical Data for Bispecific Antibody APVO603 at the Society for Immunology in Cancer Annual Meeting
11/11/2021
Aptevo Therapeutics Inc. today announced the presentation of preclinical data for APVO603, the Company's bispecific antibody targeting 4-1BB (CD137) and OX40 (CD134), at the Society for Immunology in Cancers (SITC) 2021 Annual Meeting.
-
Aptevo Therapeutics Presents Promising Clinical Data on Its Lead Leukemia Drug Candidate APVO436 at The Second Virtual Conference on Controversies in Leukemias, Euroleuk2021
10/27/2021
Aptevo Therapeutics Inc. and ADAPTIR-FLEX platform technologies, will participate at the 2nd Virtual Congress on Controversies in Leukemias (EuroLeuk), an international leukemia symposium which is being held October 28-29, 2021